ERCC4 and neoplasm: Defects or inhibition of ERCC1-XPF can affect the function of the NER, reducing the ability of tumor cells to effectively repair cisplatin-induced DNA damage and thus increasing tumor cell mortality (Kirschner and Melton, 2010; Tang et al., 2011).